IDEXX Laboratories Announces Second Quarter Results

Go back to IDEXX Laboratories Announces Second Quarter Results

Northcoast Research Upgrades IDEXX Laboratories (IDXX) to Neutral

August 3, 2016 9:32 AM EDT

Northcoast Research upgraded IDEXX Laboratories (NASDAQ: IDXX) from Sell to Neutral.

For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.

Shares of IDEXX Laboratories closed at $105.88 yesterday.

... More

IDEXX Laboratories (IDXX) PT Raised to $120 at Stifel on 'Very Impressive' Q2

August 2, 2016 1:26 PM EDT

Stifel Buy analyst Jonathan Block reiterated a Buy rating and raised his price target on IDEXX Laboratories (NASDAQ: IDXX) to $120.00 (from $92.00) following "very impressive" 2Q16 results with revenue of $467MM and EPS of $0.74, well above our $447MM and $0.61 estimates.

Block commented, "Management raised 2016... More

IDEXX Labs (IDXX) Tops Q2 EPS by 12c; Raises Outlook

August 2, 2016 7:04 AM EDT

IDEXX Labs (NASDAQ: IDXX) reported Q2 EPS of $0.74, $0.12 better than the analyst estimate of $0.62. Revenue for the quarter came in at $467 million versus the consensus estimate of $444.83 million.

GUIDANCE:

IDEXX Labs sees FY2016 EPS of $2.32-$2.39, versus the consensus of $2.21.

"We accelerated growth in the second quarter, further demonstrating the benefits of bringing our innovations to an attractive global market with an expanded commercial presence, including our move to a fully-direct sales strategy in the US companion animal market in 2015," said Jonathan Ayers, the Company's Chairman and... More